Classification of Substance Use Severity and Treatment Outcomes: NIDA CTN Studies

物质使用严重程度和治疗结果的分类：NIDA CTN 研究

• 批准号: 8311820
• 负责人: Li-Tzy Wu
• 金额: $ 35.51万
• 依托单位: DUKE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-01 至 2015-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8311820
• 关键词: Address; Alcohol or Other Drugs use; Algorithms; Area; Beck depression inventory; Biological; Classification; Clinical; Clinical Trials Network; Data; Data Analyses; Data Files; Data Set; Diagnosis; Diagnostic; Diagnostic and Statistical Manual; Drug Addiction; Drug usage; Equipment and supply inventories; Ethnic Origin; Ethnic group; Foundations; Frequencies; Future; Gender; HIV; Hybrids; Individual; Measurement; Measures; Mediator of activation protein; Mental Depression; Mental Health; Methods; Modeling; National Institute of Drug Abuse; Outcome; Participant; Patient Self-Report; Pattern; Phase; Probability; Quality of life; Race; Randomized; Randomized Clinical Trials; Research; Risk; Risk Behaviors; SF-36; Severities; Sex Characteristics; Solid; Symptoms; Treatment outcome; Work; addiction; data modeling; demographics; design; diagnosis quality; follow-up; health related quality of life; improved; indexing; insight; instrument; meetings; programs; psychological distress; racial and ethnic; racial and ethnic disparities; racial/ethnic difference; response; sex; statistics; theories; treatment trial

ABSTRACT This R21/R33 application is in response to RFA-DA-09-020. It seeks support to address one research area recommended by this RFA ¿Secondary data analyses of multiple trials in the NIDA Clinical Trials Network (CTN).¿ By capitalizing on the CTN¿s wealth of multisite treatment data from multiple trials, we seek to, in the R21 phase (Year 1), 1) identify and create analyzable flat data files from the raw trial data (stacked format), 2) generate study variables and codebooks by programming scoring algorithms for multiple standardized clinical instruments, 3) evaluate the extent of missing data, and 4) examine baseline clinical profiles (substance use and diagnoses, mental health, and quality of life) of trial participants by gender and race/ethnicity in order to guide the R33 phase of work. In the R33 phase (Years 2-4), we plan to evaluate the construct, concurrent, and predictive validity of categorical and dimensional models of substance use diagnoses. The multisite CTN trials present an unparalleled, excellent opportunity to explore and evaluate these clinically and scientifically important issues directly related to treatment outcomes and to the emerging Diagnostic and Statistical Manual Version-IV (DSM-V). Study Aims for R33 are to 1) investigate measurement equivalence of DSM-IV diagnostic questions by gender and race/ethnicity, 2) evaluate the construct and concurrent validity of DSM-IV substance use diagnoses using categorical, dimensional, and integrated hybrid models of diagnostic classification, 3) determine empirically defined drug dependence subtypes (an integrated hybrid model) in predicting subsequent outcomes and to explore the mediator and moderators of the associations, and 4) evaluate empirically-defined comorbid drug dependence subtypes in predicting subsequent outcomes and to explore the mediator and moderators of the associations. Gender/sex differences will be examined in all analyses either through stratified analyses or the inclusions of interaction terms as appropriate.

抽象的 此R21/R33应用程序响应RFA-DA-09-020。它寻求支持以解决一项研究 NIDA临床试验中多个试验的二级数据分析推荐的区域 网络（CTN）。 我们寻求在R21阶段（第1年），1）从RAW识别并创建可分析的平面数据文件 试用数据（堆叠格式），2）通过编程评分生成研究变量和代码手册 多种标准化临床工具的算法，3）评估丢失数据的程度，4） 检查基线临床特征（使用和诊断，心理健康和生活质量） 性别和种族/种族的审判参与者为了指导R33工作阶段。在R33中 阶段（2 - 4年），我们计划评估分类的结构，并发和预测有效性 和物质使用诊断的尺寸模型。多站点CTN试验提出了 无与伦比的，绝佳的机会来探索和评估这些在临床和科学上很重要的机会 与治疗结果以及与新兴诊断和统计手册有关的问题 版本IV（DSM-V）。 R33的研究目的是1）研究DSM-IV的测量等效性 性别和种族/种族诊断问题，2）评估结构和并发有效性 使用分类，维和集成的混合模型的DSM-IV物质使用诊断 诊断分类，3）确定经验定义的药物依赖性亚型（综合 混合模型）在预测后续结果并探索介体和主持人时 关联和4）评估经验定义的合并症药物依赖性亚型 随后的结果并探索关联的调解人和主持人。性别/性别 在所有分析中，将通过分层分析或包含在所有分析中检查差异 互动条款适当。